CHANGE
THE WORLD

J2HBiotech - Journey to Healthcare Solutions

ABOUT US

New drug development company

J2Hbiotech

Selected as a preliminary unicorn company for the first time
as a bio venture company

PLATFORM TECHNOLOGY

OPTIFLEX®

OPTIFLEX® is a technology that provides optimized prodrugs to develop better medicines.

It consists of OPTIPRO® to optimize properties and OPTIMED® to optimize pharmacokinetics and side effects profiles.

3D-LiDDiS®

3D-LiDDiS® is a technology for developing therapeutics for various liver diseases,

Through biomimetic 3D cell culture and 3D phenotype screening, the efficacy of non-alcoholic fatty hepatitis, liver cancer, and liver fibrosis of new drug candidates can be evaluated and drug-induced hepatotoxicity.

PIPELINE

J2H-1701 (Infectious disease, anti-HCV)
J2H-1702 (NASH)
TEJ-1704 (ALS)
J2H-1801 (Multiple sclerosis,MS)
J2H-1802 (Psoriasis)
J2H-1803 (Duchenne muscular dystrophy)
J2H-1908 (Solid tumor )
J2H-P1904 (Liver fibrosis)
J2H-P1905 (Idiopathic pulmonary fibrosis,IPF)
J2H-PROTAC (Proteolysis-targeting chimera against Non-small-cell lung carcinoma)

J2HBIOTECH in NEWS

J2H Biotech challenges 1 兆 corporate value .. Selected as a preliminary unicorn company

Bio-new drug venture J2H Biotech is challenging the enterprise value of KRW 1 trillion.

J2H Biotech, which is preparing for an IPO in 2021, has been selected as a preliminary unicorn company promoted by the Small and Medium Venture Business Department,
and will take a step closer to becoming a leading bioventure unicorn company in Korea.

- FnNews 2019.12.25 -

J2H Biotech's two-track strategy "Development of innovative new drugs / improved new drugs"

J2H Biotech, located in Suwon, Gyeonggi-do, is a bio company with a business model differentiated from existing new drug development companies.
While focusing on the development of innovative new drugs, it is also suitable for the cash cow business, such as the development and supply of improved new drugs, CMO business, and pharmaceutical raw materials (API), Pursue strategies to secure financial independence.
It also focuses on solving unmet needs through thorough market analysis rather than platform technology.

- BioSpectator 18.7.10 -

Korea's Shire offers solutions to rare incurable diseases

A significant proportion of Shire's products and R & D pipelines are treatments for rare incurable diseases.
Located in Sandan-ro, Danwon-gu, Ansan-si, J2H Biotech is a bio-venture company that dreams of becoming Korea's Shire.
J2H Biotech, which has recently attracted attention, is a bio-venture company that has been devoted to developing “new drugs” that will lead the future healthcare industry.
J2H Biotech's mission is to contribute to the promotion of human health by developing better medicines. In particular, the vision is to provide a solution to the unmet needs of rare incurable diseases.

- NewsMaker 17.3.5 -

Medical venture j2h biotech is dreaming of a new leap forward.

Venture company dreaming of new drugs
Located in Sandan-ro, Danwon-gu, Ansan-si, 'J2H Biotech (J2H)' is a venture company aiming to develop a 'new drug' that will lead the world market.
‘J2H’ is an abbreviation of ‘Journey To Healthcare solutions’ and has a name meaning travel for healthcare solutions.
On November 1, 2014, the two co-representatives, Kim Jae-sun and Hyung-cheol Hyung-cheol, founded here, are trying to create a company that can offer alternatives in various areas of incurable rare diseases and infections based on creative ideas.

- IssueMaker 17.1.2 -

OUR PARTNER

FIND US ON THE MAP

J2HBiotech

ADR : 210-B, Suwon Venture Valley2, 142-10, Saneop-ro 156beon-gil, Gwonseon-gu, Suwon-si, Gyeonggi-do, Republic of Korea

Phone : +82 31 5182 8070 ~ 8071

Fax : +82 31 5182 8080

Email : info@j2hbio.com